CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma

CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma

Multiple Myeloma (MM) is a hematological cancer characterized by proliferation of malignant plasma cells in the bone marrow (BM). MM represents the second most frequent hematological malignancy, accounting 1% of all cancer and 13% of hematological tumors, with ~9,000 new cases per year. Patients wit...

Full description

Bibliographic Details
Main Authors: Fabio Morandi, Alberto L. Horenstein, Federica Costa, Nicola Giuliani, Vito Pistoia, Fabio Malavasi
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-11-01
Series:Frontiers in Immunology
Subjects:
CD38
multiple myeloma
immunotherapy
preclinical models
clinical trials
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2018.02722/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2018.02722/full

Similar Items